VTRS Viatris Inc
3,652
$11.16
$0.06
(0.54%)
| Watchers | 3,652 |
| 52-Wk Low | $8.74 |
| 52-Wk High | $13.62 |
| Market Cap | $13.29B |
| Volume | 9.58M |
| 52-Wk High | $13.62 |
| 52-Wk Low | $8.74 |
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance RangesPR Newswire • 1 day ago
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial...
Share to Feed
Viatris to Participate in the BofA Securities 2024 Health Care Conference Viatris to Participate in the BofA Securities 2024 Health Care Conference PR Newswire PITTSBURGH, May 2, 2024 PITTSBURGH, May...
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading...
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 PR Newswire PITTSBURGH, April 16, 2024 PITTSBURGH, April...
Viatris Appoints Corinne Le Goff as Chief Commercial Officer Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR Newswire PITTSBURGH, April 15, 2024 PITTSBURGH, April 15, 2024...
Understanding the Barriers to Outperformance for Viatris IncRelated Stocks: VTRS...
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United States Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United...
Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent...